OTCPK:NVOS

Stock Analysis Report

Novo Integrated Sciences

Executive Summary

Novo Integrated Sciences, Inc., together with its subsidiaries, provides primary healthcare services.

Snowflake

Fundamentals

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Novo Integrated Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

50.0%

NVOS

4.6%

US Healthcare

2.3%

US Market


1 Year Return

-66.8%

NVOS

-8.5%

US Healthcare

5.6%

US Market

Return vs Industry: NVOS underperformed the US Healthcare industry which returned -8.5% over the past year.

Return vs Market: NVOS underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

NVOSIndustryMarket
7 Day50.0%4.6%2.3%
30 Day62.2%-0.1%-1.0%
90 Day-53.5%-4.5%-0.7%
1 Year-66.8%-66.8%-7.1%-8.5%7.9%5.6%
3 Yearn/a31.9%26.5%45.6%36.3%
5 Yearn/a63.7%53.9%65.8%47.6%

Price Volatility Vs. Market

How volatile is Novo Integrated Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Novo Integrated Sciences undervalued compared to its fair value and its price relative to the market?

5.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate NVOS's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate NVOS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NVOS is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: NVOS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate NVOS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NVOS is overvalued based on its PB Ratio (5.3x) compared to the US Healthcare industry average (2.5x).


Next Steps

Future Growth

How is Novo Integrated Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Novo Integrated Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine Novo Integrated Sciences's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Novo Integrated Sciences's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Novo Integrated Sciences performed over the past 5 years?

-21.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: NVOS is unprofitable, and losses have increased over the past 5 years at a rate of -21.7% per year.

Accelerating Growth: Unable to compare NVOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NVOS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (5.3%).


Return on Equity

High ROE: NVOS has a negative Return on Equity (-2.53%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: NVOS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: NVOS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Novo Integrated Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: NVOS's short term assets ($4.6M) exceeds its short term liabilities ($4.6M)

Long Term Liabilities: NVOS's short term assets (4.6M) exceeds its long term liabilities (1.8M)


Debt to Equity History and Analysis

Debt Level: NVOS's debt to equity ratio (9.8%) is considered satisfactory

Reducing Debt: Insufficient data to determine if NVOS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: NVOS has a low level of unsold assets or inventory.

Debt Coverage by Assets: NVOS's debt is covered by short term assets (assets are 1.846710x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NVOS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NVOS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -42.1% each year


Next Steps

Dividend

What is Novo Integrated Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate NVOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NVOS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if NVOS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NVOS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NVOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Novo Integrated Sciences's salary, the management and board of directors tenure and is there insider trading?

2.4yrs

Average management tenure


CEO

Rob Mattacchione 0

1yrs

Tenure

0

Mr. Robert Mattacchione also known as Rob is Chairman of the Board and Chief Executive Officer at Novo Integrated Sciences, Inc. since October 2018. He is the co-founder of Novo Healthnet Limited, a wholly ...


Management Age and Tenure

2.4yrs

Average Tenure

46.5yo

Average Age

Experienced Management: NVOS's management team is considered experienced (2.4 years average tenure).


Board Age and Tenure

2.4yrs

Average Tenure

52yo

Average Age

Experienced Board: NVOS's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Chris David (60yo)

    President & Director

    • Tenure: 2.4yrs
    • Compensation: US$577.97k
  • Emily Mattacchione (38yo)

    Treasurer

    • Tenure: 1.6yrs
  • Mike Gaynor (52yo)

    Secretary & Director

    • Tenure: 2.4yrs
  • David Brien

    Senior Vice President of Clinical Operations - Eastern Ontario

    • Tenure: 0yrs
  • Klara Radulyne (41yo)

    Principal Financial Officer

    • Tenure: 2.4yrs
  • Rob Mattacchione

    Chairman of the Board & CEO

    • Tenure: 1yrs

Board Members

  • Chris David (60yo)

    President & Director

    • Tenure: 2.4yrs
    • Compensation: US$577.97k
  • Mike Gaynor (52yo)

    Secretary & Director

    • Tenure: 2.4yrs
  • Pierre Dalcourt (48yo)

    Director

    • Tenure: 2.4yrs
  • Rob Mattacchione

    Chairman of the Board & CEO

    • Tenure: 1yrs

Company Information

Novo Integrated Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Novo Integrated Sciences, Inc.
  • Ticker: NVOS
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$134.215m
  • Shares outstanding: 223.69m
  • Website: https://www.novointegrated.com

Number of Employees


Location

  • Novo Integrated Sciences, Inc.
  • 11120 NE 2nd Street
  • Suite 200
  • Bellevue
  • Washington
  • 98004
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NVOSOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMay 2017

Biography

Novo Integrated Sciences, Inc., together with its subsidiaries, provides primary healthcare services. The company offers physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutic ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:41
End of Day Share Price2019/10/15 00:00
Earnings2019/05/31
Annual Earnings2018/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.